Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression on first-line gefitinib: the phase III, randomised IMPRESS study - Mok, T SK; Wu, Y; Nakagawa, K (Ann Oncol, 2014)
abstr LBA2_PR